Suven Life Sciences cash flow

·Pharma & HealthChart ›
Latest FY26
Cash from operations
−₹302cr−₹154 cr in FY25
Capital spending
₹5.1cr−86.4% on FY25
Free cash flow
−₹307cr−₹191 cr in FY25
Cash from financing
₹757cr−₹0.8 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Adjustments to reconcile profit — non-cash items
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
—5.65.35.85.8
—0.20.00.20.3
—−4.2−5.716.40.0
—−9.5−5.0−4.50.0
—1.81.30.00.0
—0.20.00.00.0
—−0.40.0−7.50.0
Changes in working capital
—0.10.5−0.70.0
—−0.2−0.1−0.50.5
—0.00.00.0−105
—−8.7−1.95.16.3
—−0.00.50.91.2
—−0.73.20.4−0.3
—−10.46.92.23.7
—1.60.1−0.0−0.1
—−0.30.50.00.3
—0.20.4−0.5−0.1
Cash from operating activities
−352−276−161−106−118
—−24.76.017.3−87.2
—−301−155−88.8−205
—0.00.00.06.4
—0.00.00.0−7.8
—0.8−0.6−6.21.1
—−302−154−82.6−208
Cash from investing activities
—5.137.3−2.42.9
—0.00.00.00.6
—0.00.0−16.40.0
—4.25.70.0−6.4
—−46118775.6−147
—−46215561.6−156
Cash from financing activities
—7570.00.0397
—0.00.00.00.5
—0.00.70.91.1
—0.00.00.20.0
—0.00.00.0−0.3
—757−0.8−1.1396
—−6.70.1−22.131.9
—0.00.00.0−0.2
—−6.70.1−22.131.7
———14.937.0
Reference items
−366−285−166−128−126
−4,155.5%−3,998.8%−2,490.7%−1,094.7%−929.8%
−307−307−191−85.0−211
——−191−85.2—
−₹11.64−₹11.64−₹7.26−₹3.22−₹7.99
—1.09×0.96×0.79×1.76×
—0.8−0.6−6.21.1
——0.00.2—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUVEN₹264.20

Suven Life Sciences Limited

· Pharma & Health
₹ CrorePeersVIMTALABSTAKEMcap ₹6,967 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation5.85.85.35.6—
+ Finance Costs0.30.20.00.2—
+ Interest Income0.016.4-5.7-4.2—
+ Fair Value (Gains) / Losses0.0-4.5-5.0-9.5—
+ Share-based Payments0.00.01.31.8—
+ Unrealised FX (Gain) / Loss0.00.00.00.2—
+ Other Reconciling Items0.0-7.50.0-0.4—
Changes in Working Capital
+ Inventories0.0-0.70.50.1—
+ Trade Receivables — Current0.5-0.5-0.1-0.2—
+ Other Financial Assets — Current-104.80.00.00.0—
+ Other Current Assets6.35.1-1.9-8.7—
+ Other Non-current Assets1.20.90.5-0.0—
+ Trade Payables — Current-0.30.43.2-0.7—
+ Other Financial Liabilities — Current3.72.26.9-10.4—
+ Other Current Liabilities-0.1-0.00.11.6—
+ Provisions — Current0.30.00.5-0.3—
+ Provisions — Non-current-0.1-0.50.40.2—
Cash from Operating Activities
Profit Before Tax (per I/S)-118.3-106.1-160.7-276.3-352.4
+ Total Adjustments (incl. Working Capital)-87.217.36.0-24.7—
Cash from Operations (pre-tax)-205.5-88.8-154.7-301.0—
+ Interest Received — Operating6.40.00.00.0—
+ Other Inflows / (Outflows) — Operating-7.80.00.00.0—
+ Income Taxes Paid1.1-6.2-0.60.8—
Cash from Operating Activities-207.9-82.6-154.1-301.8—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)2.9-2.437.35.1—
+ Disp of Other Long-term Assets0.60.00.00.0—
+ Dividends Received — Investing0.0-16.40.00.0—
+ Interest Received — Investing-6.40.05.74.2—
+ Other Inflows / (Outflows) — Investing-147.075.6186.5-461.3—
Cash from Investing Activities-155.761.6155.0-462.1—
Cash from Financing Activities
+ Proceeds from Issue of Shares397.40.00.0757.2—
+ Repayment of Borrowings0.50.00.00.0—
+ Payment of Lease Liabilities1.10.90.70.0—
+ Interest Paid0.00.20.00.0—
+ Other Inflows / (Outflows) — Financing-0.30.00.00.0—
Cash from Financing Activities395.5-1.1-0.8757.2—
Net Changes in Cash (pre-FX)31.9-22.10.1-6.7—
+ Effect of FX Rate Changes on Cash-0.20.00.00.0—
Net Changes in Cash31.7-22.10.1-6.7—
Closing Cash37.014.9———
Reference Items
EBITDA-125.9-128.0-165.8-284.5-366.3
EBITDA Margin %-929.78-1,094.72-2,490.66-3,998.80-4,155.50
Free Cash Flow (CFO − Capex)-210.8-85.0-191.4-306.9-306.9
Free Cash Flow to Equity—-85.2-191.4——
Free Cash Flow per Basic Share-7.99-3.22-7.26-11.64-11.64
Cash Flow to Net Income1.760.790.961.09—
Cash Paid for Taxes1.1-6.2-0.60.8—
Cash Paid for Interest—0.20.0——
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.